Sugi Predict

Sugi Predict / Compounds / SCHEMBL4245385

SCHEMBL4245385

SCHEMBL4245385

NC(c1ccccc1-c1ccccc1C(=O)NCCc1ccccc1)S(=O)(=O)c1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ TP53 P04637 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KCNA5 P22460 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CCND1 P24385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242916 0.90 CHRNB2 (0.46) RAB9ACA1CA2CA9ALDH1A1
SCHEMBL4238995 0.86 HTT (0.47) RAB9ANPC1CA2ALDH1A1SMN1; SMN2
SCHEMBL4247417 0.85 ALDH1A1 (0.53) RAB9ANPC1CA1CA2CA9
SCHEMBL4236018 0.82 ALDH1A1 (0.50) RAB9ANPC1CA1CA2CA9
SCHEMBL4240140 0.82 GBA1 (0.43) ALDH1A1LMNA
SCHEMBL4248643 0.82 CA1 (0.46) RAB9ANPC1CA1CA2CA9
SCHEMBL2210421 0.78 KCNA5 (0.60) RAB9ANPC1POLBKCNA5
SCHEMBL4248727 0.77 ALDH1A1 (0.50) RAB9APOLBALDH1A1KCNA5LMNA
SCHEMBL4244514 0.76 HTT (0.55) RAB9ANPC1CA1CA2POLB
SCHEMBL4245434 0.70 KCNA5 (0.46) RAB9ANPC1ALDH1A1SMN1; SMN2KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 — — US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 — — US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 RAB9A 1604/4885NPC1 3553/4885CA1 2291/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E RAB9A 1564/4885NPC1 3517/4885CA1 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.